Piper Sandler analyst Allison Bratzel raised the firm’s price target on Travere Therapeutics (TVTX) to $35 from $26 and keeps a Neutral rating on the shares. The firm notes Filspari had a strong Q3, with U.S. revenue of $90.9M coming in about $12M above consensus, representing +26% quarter-over-quarter growth and an impressive 155% year-over-year growth. Piper sees the upcoming regulatory decision for FSGS as the primary near-term driver for shares, with regulatory uncertainty leading the firm to remain on the sidelines.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
- Travere Therapeutics’ Strong Quarter and Future Prospects
- Citi ups Travere target, opens ‘upside 90-day catalyst watch’
- Travere Therapeutics price target raised to $40 from $30 at TD Cowen
- Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones